Age-Related Macular Degeneration Treatment Market Value to Exceed $10 Billion by 2023

The Age-related Macular Degeneration (AMD) treatment market across seven major countries (the US, UK, Germany, France, Spain, Italy and Japan) will almost double in value from $5.1 billion in 2013 to $10.1 billion by 2023, according to research and consulting firm GlobalData.

The company’s latest report* states that the main drivers for this considerable expansion, which will occur at a Compound Annual Growth Rate (CAGR) of 7.1%, are the new therapies entering the market and a global aging society, which will lead to increasing numbers of elderly people developing the age-related retinal disease.

Catherine Daly, PhD, GlobalData’s Analyst covering Neurology and Ophthalmology, says: “The global AMD treatment market is overwhelmingly dominated by anti-vascular endothelial growth factor (anti-VEGF) drugs, including Lucentis, Avastin, and Eylea, which together accounted for 98% of sales for AMD in 2013.

“However, the anti-VEGF monopoly is set to take a dramatic tumble due to the launch of novel adjunctive therapies for wet AMD, Fovista and squalamine, and the introduction of two therapies for dry AMD, lampalizumab and emixustat, during the forecast period. These entrants will cause the anti-VEGFs’ stronghold on the market to drop to 64% by 2023.”

GlobalData’s report also states that the US had the largest AMD treatment market among the seven major countries in 2013, due to its large population, relatively higher drug prices, and overall higher drug treatment rates.

The US accounted for 49% of the global AMD therapeutics market in 2013 and will achieve a 55% share by 2023, with its market value forecast to more than double from $2.5 billion to $5.6 billion over the same period.

Daly comments: “The new therapies entering the market will be the main drivers of growth in the US, with the wet AMD drugs Fovista, squalamine, and abicipar pegol launching in 2017, 2018, and 2020, respectively.

“Fovista is undergoing an extensive Phase III development programme, and the data released to date have shown that this drug provides added benefit over the standard of care (anti-VEGF monotherapy). This indicates that the drug will enjoy good market success during the forecast period, with its US sales reaching $603 million by 2023.”

*PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023